Drug Profile
H3B 6545
Alternative Names: H3B-6545Latest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator H3 Biomedicine
- Developer Eisai Co Ltd; H3 Biomedicine
- Class Amides; Amines; Antineoplastics; Fluorocarbons; Indazoles; Pyridines; Small molecules
- Mechanism of Action Estrogen receptor alpha antagonist
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HER2 negative breast cancer
Most Recent Events
- 26 Oct 2023 Eisai completes a phase I/II trial for Her2 negative Breast cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in France (PO) (NCT03250676)
- 04 Aug 2023 H3B 6545 is still in phase I trials for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (Eisai pipeline, August 2023)
- 28 May 2023 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)